Biocatalysis

Jonathan Dordick

Howard P Isermann Professor and Director, Rensselaer Polytechnic Institute (RPI), New York, United States

"Truly effective final-stage drug testing needs an environment that mimics the actual conditions of the human body." Jonathan Dordick

Full bio, links and summary
"Biocatalysis and human cell culture offer the opportunity to test activity and toxicity of drugs in an environment that mimics the human body." Jonathan Dordick Full bio, links and summary

Speaker

Jonathan Dordick received his BA degree in Biochemistry and Chemistry from Brandeis University and his PhD from the Massachusetts Institute of Technology in Biochemical Engineering. In 1987, Dr Dordick joined the Department of Chemical and Biochemical Engineering at the University of Iowa. He was promoted to Associate Professor in 1991, to Full Professor in 1994, and served as Department Chair from 1995–1998. He was also Associate Director of the Center for Biocatalysis and Bioprocessing at the University of Iowa and held a joint position in the Department of Medicinal and Natural Products Chemistry in the College of Pharmacy. In 1998, Prof Dordick joined the faculty at Rensselaer Polytechnic Institute as Chair of the Department of Chemical Engineering where he is also the Howard P Isermann Professor of Biochemical Engineering. Professor Dordick’s current research includes molecular bioprocessing (including high-throughput bioprocessing in drug and functional materials discovery), biomaterials development, biocatalytic nanocomposites, and protein structure and function in abiotic environments. Professor Dordick received the NSF Presidential Young Investigator Award in 1989, a University of Iowa Faculty Scholars Award, and was elected as a Fellow of the American Institute of Medical and Biological Engineers in 1996. He is highly active in the biotechnology community, serving as Chair of the Division of Biochemical Technology of the ACS in 1992, and presently he serves on the Scientific Advisory Boards for several biotechnology companies. Dr Dordick is a co-founder of EnzyMed, Inc. a pharmaceutical and agrochemical discovery company. Dr Dordick has published 118 papers and is an inventor or co-inventor on 14 patents.   

Presentation Summary

Adverse drug reactions are a leading cause of death in the United States, deaths which are preventable with a better understanding of how drugs interact with the human body. Rigorous drug testing is required to ensure that drugs which may cause adverse reactions are eliminated before they are made available. The final stage in drug testing requirements remains the weak link, because drugs are tested on animals. Animal reactions do not necessarily correlate with human reactions to the same chemicals. For testing to truly predict how humans will react, the drug needs to be evaluated on human cells. Biocatalysis and human cell culture offer the opportunity to test activity and toxicity of drugs in an environment that mimics the human body. Biocatalysis offers a more efficient and more robust testing environment, with reduced testing cost, the development of better drugs and a reduced incidence of adverse reactions among human recipients.